Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma) research hub

A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours (SABR-PDL1)

This study tests whether combining an immunotherapy drug called atezolizumab with a targeted type of radiotherapy (SABR) can help control advanced cancer. It is designed for adults with metastatic bowel, lung, kidney, or soft tissue cancers to see if the treatment keeps tumours from growing for at least one year.